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Abstract
Nipah virus (NiV) continues to cause outbreaks of fatal human encephalitis due to spillover from
its bat reservoir. We determined that a single dose of replication-defective vesicular stomatitis
virus (VSV)-based vaccine vectors expressing either the NiV fusion (F) or attachment (G)
glycoproteins protected hamsters from over 1000 times LD50 NiV challenge. This highly effective
single-dose protection coupled with an enhanced safety profile makes these candidates ideal for
potential use in livestock and humans.
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Nipah virus (NiV) is a highly pathogenic paramyxovirus responsible for causing fatal human
encephalitis with high case fatality rates from 40%–75% (Lo and Rota, 2008). Since its
initial outbreak in Malaysia from 1998–1999, NiV has caused smaller sporadic outbreaks of
fatal encephalitis in Bangladesh on a near-annual basis (Luby and Gurley, 2012). A soluble
subunit glycoprotein vaccine approved for animal use against the closely-related Hendra
virus requiring a two-dose prime-boost regimen has shown protection against NiV in several
animal models (Bossart et al., 2012; Broder et al., 2013; McEachern et al., 2008; Mungall et
al., 2006; Pallister et al., 2013). Previous work demonstrated that a single dose of
replication-defective single-cycle recombinant vesicular stomatitis viruses (VSV-ΔG)
expressing either the NiV fusion (F) (VSV-ΔG-NiVF) or attachment (G) (VSV-ΔG-NiVG)
glycoproteins induced neutralizing antibodies in mice against VSV-ΔG-particles
pseudotyped with NiV F and G glycoproteins (VSV-ΔG-eGFP-NEUT) (Chattopadhyay and
#Address correspondence to Michael K. Lo mko2@cdc.gov , and Christina F. Spiropoulou ccs8@cdc.gov.
1M.K.L., B.H.B., and A.C. contributed equally to this work.
Mailing address: Centers for Disease Control and Prevention, Viral Special Pathogens Branch 1600 Clifton Road, Mailstop G-14,
Atlanta, Georgia 30333
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our
customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of
the resulting proof before it is published in its final citable form. Please note that during the production process errors may be
discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
NIH Public Access
Author Manuscript
Antiviral Res. Author manuscript; available in PMC 2015 January 01.
Published in final edited form as:













Rose, 2011). In order to evaluate the protective efficacy of the VSV-ΔG-NiVF and VSV-
ΔG-NiVG vaccines against lethal NiV challenge in an animal model that mimics NiV
disease, we tested these vaccines in the Syrian golden hamster (DeBuysscher et al., 2013;
Guillaume et al., 2004; Rockx et al., 2011; Wong et al., 2003). We obtained approval for
animal experiments from the Centers for Disease Control and Prevention (CDC)
Institutional Animal Care and Use Committee (IACUC). All animal work was performed by
certified staff in Association for Assessment and Accreditation of Laboratory Animal Care
(AAALAC)-approved biosafety level 2(BSL-2) (vaccination phase) or BSL-4 (challenge
phase) facilities at CDC.
We produced stocks of the single-cycle viruses VSV-ΔG-NiVG, VSV-ΔG-NiVF, VSV-ΔG-
eGFP pseudotyped with VSV G glycoprotein, and also the VSV-ΔG-eGFP-NEUT
pseudotyped with NiV F and G as previously described (Chattopadhyay and Rose, 2011).
For vaccination 6-week old female Syrian golden hamsters (Mesocricetus auratus, Charles
River Laboratories, Wilmington, VA) were anesthetized (isoflurane) and inoculated
intramuscularly in the right quadriceps with 1 x 106 infectious particles of either VSV-ΔG-
NiVG (10 animals), VSV-ΔG-NiVF (10 animals), or VSV-ΔG-eGFP (10 animals). At 28
days post-vaccination, ~ 100 μl of blood was collected for determination of serum
neutralizing antibody titers (SNT) as previously described (Chattopadhyay and Rose, 2011).
The vaccinated hamsters, along with 3 additional unvaccinated hamsters (to serve as
unvaccinated controls) were transferred into the BSL-4 lab and were given 3 days to adjust
to their new surroundings. On day 32 post-vaccination (challenge day 0), all hamsters were
inoculated via the intraperitoneal route with a previously described uniformly lethal
challenge dose (105 TCID50/hamster, >1000 times LD50) of NiV Malaysia strain passaged 3
times on Vero E6 cells (Chua et al., 2000; DeBuysscher et al., 2013; Harcourt et al., 2000;
Rockx et al., 2011). Animals were examined and scored daily for two weeks post-challenge
for signs of clinical illness, neurologic disease, respiratory distress, and weight loss (weight
evaluation for 3 vaccinated groups began on day 3 post-challenge). Animals showing
significant weight loss (>25% of initial weight on challenge day 0) alongside any
neurological or respiratory signs were humanely euthanized. Animals without clinical illness
after 14 days post-infection (p.i.) continued to be monitored daily but were only weighed in
2–5 day intervals until day 32 p.i. in which all surviving animals were humanely euthanized.
At time of euthanasia, ~ 3 ml of blood was collected by cardiac puncture for SNT
determination. Necropsies were performed to collect lung, spleen, kidney, and brain tissues.
Tissues were either inactivated in MAGMAX RNA lysis buffer (Life Technologies,
Carlsbad, CA) for subsequent RNA extraction and real-time RT-PCR as previously
described (Lo et al., 2012), or fixed in 10% formalin for histopathology and
immunohistochemistry (IHC) analysis as previously described (Wong et al., 2003).
On day 6 post-challenge, all unvaccinated control hamsters either died or were euthanized
due to the development of neurologic signs and respiratory distress. Similarly, 5 out of 10
(50%) backbone control VSV-ΔG-eGFP-vaccinated hamsters either died or were euthanized
due to the onset of illness. By day 9 post-challenge, all VSV-ΔG-eGFP-vaccinated hamsters
had either died or were euthanized (Figure 1A). In contrast, hamsters vaccinated with VSV-
ΔG-NiVG or VSV-ΔG-NiVF did not develop any clinical illness nor weight loss throughout
the course of infection, and were euthanized on day 32 p.i. (day 64 post-vaccination) (Figure
1A, 1B). SNTs against NiV were defined as the reciprocal of the highest serum dilution at
which duplicate wells of each serum sample showed complete neutralization of 50 infectious
particles of VSV-ΔG-eGFP-NEUT. Prior to NiV challenge, hamsters vaccinated with either
VSV-ΔG-NiVG or VSV-ΔG-NiVF developed respective SNTs of 640 and 160, while
hamsters vaccinated with VSV-ΔG-eGFP did not develop any detectable SNT (Figure 2A).
Following NiV challenge, both unvaccinated control and VSV-ΔG-eGFP-vaccinated groups
developed low levels of neutralizing antibodies (Figure 2B), but even at serum dilutions of
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1:20 could not completely neutralize 50 particles of VSV-ΔG-eGFP-NEUT. The lack of an
anamnestic immune response in the VSV-ΔG-NiVG or VSV-ΔG-NiVF-vaccinated groups
following NiV challenge possibly indicates sterilizing immunity, as their respective post-
challenge SNTs at the time of euthanasia remained similar to pre-challenge levels with
comparatively lower percentages of neutralization at higher serum dilutions of 1:2560,
1:5120 and 1:10240 (Figure 2A, 2B). Histopathology and IHC results in unvaccinated and
VSV-ΔG-eGFP-vaccinated hamsters were similar to those observed in a recent study of NiV
pathogenesis in the hamster model (DeBuysscher et al., 2013), indicating bronchointerstitial
pneumonia with vasculitis associated with virus replication (Figure 3). In the unvaccinated
and eGFP control-vaccinated groups we detected both viral RNA and viral antigen in all
tissues sampled from both groups except for the brain, in which we detected viral RNA but
not viral antigen (Table 1, Figure 3, data not shown). In contrast, we did not observe any
pathology and could neither detect the presence of viral RNA nor antigen in any tissues
collected from VSV-ΔG-NiVG or VSV-ΔG-NiVF-vaccinated groups (Table 1, data not
shown).
In summary, we have demonstrated that a single dose of these single-cycle vaccine
candidates expressing either NiV G or F conferred complete protection from lethal NiV
challenge in the Syrian golden hamster animal model. This is in marked contrast with all
other previously evaluated viral vaccine vectors expressing NiV G or F that required multi-
dose prime-boost regimens (Guillaume et al., 2004; Weingartl et al., 2006; Yoneda et al.,
2013) with the exception of an adenovirus-associated virus (AAV) vector which required an
extremely high dose of vaccine (6 x 1011 genome particles) for protection (Ploquin et al.,
2013). Furthermore, when compared to these other vectors expressing NiV G, the VSV-ΔG-
NiVG induced higher levels of SNT at 28 days post-vaccination, and was the only vaccine
administered in which no anamnestic immune response was detected. Additionally, the NiV
challenge dose used in this study was at least 10 times greater than that used by any other
NiV vaccine protection study in the hamster model, which highlights the extremely robust
protection conferred by the VSV-ΔG NiV vaccines. While replication-competent VSV-
based vectors expressing appropriate foreign antigens have shown to be highly effective
vaccines against a number of viral and bacterial pathogens (Cobleigh et al., 2010; Jones et
al., 2005; Kahn et al., 2001; Kapadia et al., 2005; Liao et al., 2008; Palin et al., 2007;
Roberts et al., 1998; Roberts et al., 2004; Rose et al., 2001), regulatory approval of these
vaccine vectors in humans has been slow due to concerns regarding potential pathogenesis.
On the other hand, replication-deficient VSV-ΔG vectors have shown to induce equivalent
or even greater levels of humoral and cell-mediated immunity when compared with its
corresponding replication-competent vector, particularly when vaccinating via the
intramuscular route (Kapadia et al., 2008; Publicover et al., 2005). In comparison to the
soluble HeV G subunit vaccine (HeVsG) currently in animal trials (Broder et al., 2013), the
VSV-ΔG vector provides some advantages. The first and foremost advantage is the single-
dose requirement for protection, and the second advantage is the lack of any adjuvants
required to generate robust humoral and cell-mediated T-helper 1 (Th1) type immunity
(Publicover et al., 2005). The two-dose HeVsG vaccine formulation requires the action of
two adjuvants, Allhydrogel and CpG oligodeoxynucleotide (ODN) 2006 (Bossart et al.,
2012) in order to generate a Th1 immune response, since Allhydrogel alone typically
induces a Th2 response which is not appropriate against viral infections (Coffman et al.,
2010; Steinhagen et al., 2011; Weeratna et al., 2001). The HeVsG vaccine however holds an
advantage over the VSV-ΔG vector in that the vaccine antigen is more easily produced on a
large scale versus the production of infectious VSV-ΔG particles which require multiple
plasmid transfections (Pallister et al., 2011; Witko et al., 2010). The results reported in this
study underscore the safety profile and robust protection conferred by a single dose of these
replication-deficient single-cycle vectors against NiV. Future studies will establish the
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minimum protective dose and early protection kinetics of the VSV-ΔG NiV vaccines as
potential tools for prophylaxis and reduction of NiV disease severity and/or mortality.
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• A single dose of VSVΔG-based vaccines expressing Nipah glycoproteins
protected hamsters.
• VSVΔG-based NiV vaccines induced high levels of serum neutralizing
antibodies with one dose.
• Lack of detectable anamnestic immune responses indicates potential sterilizing
immunity.
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A single-dose vaccination of hamsters with single-cycle replication-deficient VSV viral
vectors (VSV-ΔG) expressing either NiV G or NiV F confers complete protection from
lethal NiV challenge. (A) Survival curves of unvaccinated hamsters and hamsters vaccinated
with VSV-ΔG-NiVG, VSV-ΔG-NiVF, or VSV-ΔG-eGFP, and challenged 32 days later with
virulent NiV. (B) Weight curves of vaccinated hamsters challenged with lethal dose of NiV.
Weight changes are expressed as the mean percentage changes for NiV challenged animals
relative to their weights at day zero.
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A single-dose vaccination of hamsters with either VSV-ΔG-NiVG or VSV-ΔG-NiVF
induces protective serum neutralizing antibody titers (SNT). Percent neutralization curves of
pooled serum from each group of hamsters at (A) 28 days post vaccination pre-NiV
challenge, and (B) 64 days post-vaccination, 32 days post-NiV challenge for VSV-ΔG-
NiVG or VSV-ΔG-NiVF-vaccinated hamsters, 6 days post-challenge for unvaccinated
hamsters, and at 6, 7, and 9 days post-challenge for VSV-ΔG-eGFP-vaccinated hamsters.
SNT for each group was determined as the highest reciprocal serum dilution in which 50
particles of VSV-ΔG-eGFP virus pseudotyped with NiV F and G glycoproteins were
completely (100%) neutralized.
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Lungs from unvaccinated hamsters show vasculitis and abundant Nipah virus antigen
associated with bronchial arteries. (A) Vasculitis characterized by acute inflammation and
necrotic cellular debris that obscures the arterial wall (arrows). The adjacent parenchyma
shows interstitial pneumonia (asterisks). (B) Nipah virus IHC shows abundant antigen (red)
in endothelial cells (arrow heads) and smooth muscle cells of artery (arrows). Inset: Nipah
virus antigen within endothelial cell (arrow head). Original magnification: 100x, 400x
(inset).
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TABLE 1
Mean NiV nucleoprotein gene RNA copy numbers/μg RNA from tissue
Tissue
Unvaccinated Control (N=3) VSV-ΔG-eGFP (N=10) VSV-ΔG-NiVG (N=10) VSV-ΔG-NiVF (N=10)
Spleen 4.26E+06 1.66E+06 ND ND
Kidney 3.56E+06 1.63E+06 ND ND
Lung 9.68E+05 7.35E+06 ND ND
Brain 2.70E+05 2.70E+05 ND ND
ND= not detected
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